Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA® (fecal ...

A 2018 study of adults and children who were taking antibiotics and co-administered a probiotic supplement showed a lower risk of Clostridium difficile infections. The study authors concluded ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated manufacturing facility Since launch, Ferring created REBYOTA ...

“Access to FDA-approved treatments to prevent recurrent C. difficile infection remains critical for halting the vicious cycle of debilitating symptoms and suffering affecting patients with this ...

If you are having surgery, you may be concerned about a bacterial infection after your procedure. While these infections are often preventable with good wound care and frequent hand washing, some ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for C. diff infection. Launched on January 23, 2023, REBYOTA has been administered to ...

“Access to FDA-approved treatments to prevent recurrent C. difficile infection remains critical for halting the vicious cycle of debilitating symptoms and suffering affecting patients with this ...